With $19 billion in dry powder, Ardian is targeting big-ticket transactions in the secondaries space. Asia is becoming an increasingly significant part
Asia is becoming a more significant part of Ardian’s world, in terms of fundraising and deal sourcing. Both could be seen to reflect a growing affinity with secondaries as a strategy among an investor...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.